Research programme: microbial therapeutics - Vedanta Biosciences

Drug Profile

Research programme: microbial therapeutics - Vedanta Biosciences

Alternative Names: Microbiome-based therapeutics - Vedanta; VE 416; VE 800

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vedanta Biosciences
  • Developer Keio University School of Medicine; NYU Langone Medical Center; Vedanta Biosciences
  • Class Anti-infectives; Anti-inflammatories; Antiallergics; Antineoplastics; Immunotherapies
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants; Immunomodulators; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Food hypersensitivity; Graft-versus-host disease; Infections; Inflammatory bowel diseases

Most Recent Events

  • 10 Jul 2018 Vedanta Biosciences and Keio University School of Medicine agree co-develop microbiome-derived therapeutic for Inflammatory bowel disease
  • 10 Jul 2018 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)
  • 18 Jun 2018 Preclinical development for Infections is ongoing in USA (Vedanta Biosciences pipeline, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top